Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 409

This story is part of a series on the current progression in Regenerative Medicine. This piece discusses advances in Alzheimer’s therapy.

In 1999, I defined regenerative medicine as the collection of interventions that restore normal function to tissues and organs damaged by disease, injured by trauma, or worn by time. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.

An emerging combination of focused ultrasound therapy with a recently approved medication could be our best treatment for Alzheimer’s disease to date. In the New England Journal of Medicine, Dr. Ali Rezai and colleagues from West Virginia University describe an approach to reduce cerebral amyloid-beta load, a biomarker for neurodegeneration, in patients with Alzheimer’s. While in its preliminary stages, the combination treatment can potentially help thousands, if not millions, suffering from the disease in the near future.

Read more | >

Low mental health associated with worse outcomes after total hip arthroplasty suggests a new study published in the Archives of Orthopaedic and Trauma Surgery.

Poor mental health is difficult to recognize and as a result, its association with recovery from total joint arthroplasty is difficult to assess. The purpose of this study was to investigate the relationship between overall mental health scores and outcomes in the early postoperative period following unilateral total hip arthroplasty (THA). This is a retrospective review of prospectively collected data involving 142 patients who underwent primary unilateral THA. Independent variables included patient demographics and preoperative Patient-Reported Outcomes Measurement Information System (PROMIS), Global Physical Health (GPH) and Global Mental Health (GMH) and Hip Disability and Osteoarthritis Outcome Score, Joint Replacement (HOOS JR) scores as well as diagnoses of depression or anxiety.

Read more | >

Respiratory syncytial virus (RSV), a common infection in children and senior adults, can also infect nerve cells and trigger inflammation leading to nerve damage, according to a new Tulane University study.

RSV can cause mild symptoms such as coughing, sneezing and fever or lead to more severe conditions such as pneumonia or bronchiolitis.

But since the disease was first discovered in 1956, it has been thought to only infect the respiratory tract.

Read more | >

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function. The disease affects more than 12 million people worldwide, and many patients end up needing dialysis or a kidney transplant by the time they reach their 60s.

Researchers at MIT and Yale University School of Medicine have now found that a compound originally developed as a potential cancer treatment holds promise for treating ADPKD. The drug works by exploiting kidney cyst cells’ vulnerability to oxidative stress — a state of imbalance between damaging free radicals and beneficial antioxidants.

In a study employing two mouse models of the disease, the researchers found that the drug dramatically shrank kidney cysts without harming healthy kidney cells.

Read more | >

Originally published on Illumina News Center

Call it archaeology by other means. Rather than sifting through tons of dirt and carefully cataloguing human artifacts, Eske Willerslev and his colleagues have used Illumina NovaSeq Systems to sequence 5,000 ancient human genomes, revealing previously unseen historical nuance. This research tour de force, which is being published this month in four papers in the journal Nature, offers a rich view of early human migrations, mating habits, and disease variants, and their impact on modern Europeans.

“We wanted to sequence this ancient DNA so we could better understand human history,” says Willerslev, who is professor and director at the Centre of Excellence in GeoGenetics at the University of Copenhagen and the Prince Philip Professor of Ecology & Evolution at Cambridge University. “These results describe where we came from and why there’s so much variation in disease risk.”

Read more | >

Biomedical engineers at Duke University have developed a new method to improve the effectiveness of machine learning models. By pairing two machine learning models, one to gather data and one to analyze it, researchers can circumvent limitations of the technology without sacrificing accuracy.

This new technique could make it easier for researchers to use machine learning algorithms to identify and characterize molecules for use in potential new therapeutics or other materials.

The research is published in the journal Artificial Intelligence in the Life Sciences.

Read more | >

The type I CRISPR protein Cas3 works like Pac-Man, chomping away at a continuous stream of nucleotides with intrinsic activity for introducing targeted large deletions from a few hundred base pairs to as large as 200 kb. However, without the molecular equivalent to the four colored ghosts who chase and capture Pac-Man, the broad and unidirectional genome editing activity of Cas3 is essentially unregulated.

Yan Zhang, PhD, assistant professor in the department of biological chemistry at the University of Michigan Medical School, and her collaborators at Cornell University identified two anti-CRISPR proteins that can “turn off” Cas3, paving the way toward safer and better-controlled CRISPR applications.

The research article, “Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications,” was published in Molecular Cell.

Read more | >